{"id":30254,"date":"2022-06-28T00:31:00","date_gmt":"2022-06-27T16:31:00","guid":{"rendered":"https:\/\/flcube.com\/?p=30254"},"modified":"2025-03-25T00:33:56","modified_gmt":"2025-03-24T16:33:56","slug":"antengene-and-beigene-collaborate-on-selinexor-and-tislelizumab-combination-trial-for-lymphoma","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=30254","title":{"rendered":"Antengene and BeiGene Collaborate on Selinexor and Tislelizumab Combination Trial for Lymphoma"},"content":{"rendered":"\n

China-based Antengene Corporation Ltd (HKG: 6996<\/a>) has announced a clinical trial collaboration with BeiGene Inc. (Nasdaq: BGNE) to evaluate the combination of Antengene\u2019s selinexor (trade name: Xpovio) with BeiGene\u2019s anti-PD-1 drug tislelizumab (Baizean). The open-label, multi-center Phase I\/II trial aims to explore this combination as a potential treatment for patients with T and NK-cell lymphoma.<\/p>\n\n\n\n

Trial Details<\/strong>
The collaboration involves testing the combination regimen in an open-label, multi-center Phase I\/II clinical trial. This trial will assess the safety, tolerability, and efficacy of the selinexor-tislelizumab combination in patients with T and NK-cell lymphoma, a group of aggressive and often treatment-resistant malignancies. Specific financial terms of the collaboration were not disclosed.<\/p>\n\n\n\n

Drug Background<\/strong>
Selinexor, discovered by US-based Karyopharm Therapeutics Inc. (Nasdaq: KPTI), is the world’s first and only FDA-approved oral XPO1 inhibitor, used to treat hematological malignancies. Antengene licensed the rights to selinexor in Greater China, South Korea, and ASEAN countries in May 2018, with the first approval in China granted in November 2021 for relapsed or refractory multiple myeloma (R\/R MM). BeiGene\u2019s tislelizumab, an internally developed anti-PD-1 drug, has received nine indication approvals in China, including three for lung cancer and as a third-line treatment for classic Hodgkin\u2019s lymphoma.<\/p>\n\n\n\n

Strategic Significance<\/strong>
This collaboration represents a significant step forward in exploring novel treatment options for T and NK-cell lymphoma patients. By combining selinexor’s mechanism of action as an XPO1 inhibitor with tislelizumab’s immune checkpoint inhibition, the trial aims to address an area of high unmet medical need. The results of this Phase I\/II study could potentially expand the therapeutic landscape for these challenging malignancies.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

China-based Antengene Corporation Ltd (HKG: 6996) has announced a clinical trial collaboration with BeiGene Inc….<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[136,185,2092,16,29,18],"class_list":["post-30254","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-antengene","tag-beigene","tag-beone-medicines","tag-cancer","tag-combination-therapy","tag-pd-1-l1"],"yoast_head":"\nAntengene and BeiGene Collaborate on Selinexor and Tislelizumab Combination Trial for Lymphoma - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Antengene Corporation Ltd (HKG: 6996) has announced a clinical trial collaboration with BeiGene Inc. (Nasdaq: BGNE) to evaluate the combination of Antengene\u2019s selinexor (trade name: Xpovio) with BeiGene\u2019s anti-PD-1 drug tislelizumab (Baizean). The open-label, multi-center Phase I\/II trial aims to explore this combination as a potential treatment for patients with T and NK-cell lymphoma.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=30254\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Antengene and BeiGene Collaborate on Selinexor and Tislelizumab Combination Trial for Lymphoma\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=30254\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2022-06-27T16:31:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-03-24T16:33:56+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30254#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30254\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Antengene and BeiGene Collaborate on Selinexor and Tislelizumab Combination Trial for Lymphoma\",\"datePublished\":\"2022-06-27T16:31:00+00:00\",\"dateModified\":\"2025-03-24T16:33:56+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30254\"},\"wordCount\":286,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Antengene\",\"BeiGene\",\"BeOne Medicines\",\"Cancer\",\"Combination therapy\",\"PD-1\\\/L1\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=30254#respond\"]}],\"copyrightYear\":\"2022\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30254\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=30254\",\"name\":\"Antengene and BeiGene Collaborate on Selinexor and Tislelizumab Combination Trial for Lymphoma - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2022-06-27T16:31:00+00:00\",\"dateModified\":\"2025-03-24T16:33:56+00:00\",\"description\":\"China-based Antengene Corporation Ltd (HKG: 6996) has announced a clinical trial collaboration with BeiGene Inc. (Nasdaq: BGNE) to evaluate the combination of Antengene\u2019s selinexor (trade name: Xpovio) with BeiGene\u2019s anti-PD-1 drug tislelizumab (Baizean). The open-label, multi-center Phase I\\\/II trial aims to explore this combination as a potential treatment for patients with T and NK-cell lymphoma.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30254#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=30254\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30254#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Antengene and BeiGene Collaborate on Selinexor and Tislelizumab Combination Trial for Lymphoma\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Antengene and BeiGene Collaborate on Selinexor and Tislelizumab Combination Trial for Lymphoma - Insight, China's Pharmaceutical Industry","description":"China-based Antengene Corporation Ltd (HKG: 6996) has announced a clinical trial collaboration with BeiGene Inc. (Nasdaq: BGNE) to evaluate the combination of Antengene\u2019s selinexor (trade name: Xpovio) with BeiGene\u2019s anti-PD-1 drug tislelizumab (Baizean). The open-label, multi-center Phase I\/II trial aims to explore this combination as a potential treatment for patients with T and NK-cell lymphoma.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=30254","og_locale":"en_US","og_type":"article","og_title":"Antengene and BeiGene Collaborate on Selinexor and Tislelizumab Combination Trial for Lymphoma","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=30254","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2022-06-27T16:31:00+00:00","article_modified_time":"2025-03-24T16:33:56+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=30254#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=30254"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Antengene and BeiGene Collaborate on Selinexor and Tislelizumab Combination Trial for Lymphoma","datePublished":"2022-06-27T16:31:00+00:00","dateModified":"2025-03-24T16:33:56+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=30254"},"wordCount":286,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Antengene","BeiGene","BeOne Medicines","Cancer","Combination therapy","PD-1\/L1"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=30254#respond"]}],"copyrightYear":"2022","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=30254","url":"https:\/\/flcube.com\/?p=30254","name":"Antengene and BeiGene Collaborate on Selinexor and Tislelizumab Combination Trial for Lymphoma - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2022-06-27T16:31:00+00:00","dateModified":"2025-03-24T16:33:56+00:00","description":"China-based Antengene Corporation Ltd (HKG: 6996) has announced a clinical trial collaboration with BeiGene Inc. (Nasdaq: BGNE) to evaluate the combination of Antengene\u2019s selinexor (trade name: Xpovio) with BeiGene\u2019s anti-PD-1 drug tislelizumab (Baizean). The open-label, multi-center Phase I\/II trial aims to explore this combination as a potential treatment for patients with T and NK-cell lymphoma.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=30254#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=30254"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=30254#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Antengene and BeiGene Collaborate on Selinexor and Tislelizumab Combination Trial for Lymphoma"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/30254","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=30254"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/30254\/revisions"}],"predecessor-version":[{"id":30255,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/30254\/revisions\/30255"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=30254"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=30254"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=30254"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}